
Rajshekhar Chakraborty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1118326/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A systematic review of religious beliefs about major end-of-life issues in the five major world religions. Palliative and Supportive Care, 2017, 15, 609-622.	0.6	107
2	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia, 2017, 31, 1562-1569.	3.3	92
3	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	3.3	64
4	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. Biology of Blood and Marrow Transplantation, 2019, 25, e155-e162.	2.0	56
5	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	1.3	51
6	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	0.6	50
7	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biology of Blood and Marrow Transplantation, 2017, 23, 598-605.	2.0	47
8	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	1.5	45
9	Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	1.4	43
10	Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Reviews, 2020, 39, 100616.	2.8	43
11	Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1546-1553.	2.0	40
12	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal, 2016, 6, e512-e512.	2.8	38
13	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplantation, 2017, 52, 1126-1132.	1.3	30
14	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	1.3	30
15	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica, 2017, 102, 1439-1445.	1.7	29
16	Venous thromboembolism risk with contemporary lenalidomideâ€based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and metaâ€analysis. Cancer, 2020, 126, 1640-1650.	2.0	28
17	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia, 2018, 32, 712-718.	3.3	27
18	Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies.	0.6	27

Transplantation and Cellular Therapy, 2021, 27, 222-229.

#	Article	IF	CITATIONS
19	Realâ€world data on safety and efficacy of venetoclaxâ€based regimens in relapsed/refractory t(11;14) multiple myeloma. British Journal of Haematology, 2020, 189, 1136-1140.	1.2	25
20	Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematology,the, 2020, 7, e892-e901.	2.2	23
21	Treatment and diseaseâ€related complications in multiple myeloma: Implications for survivorship. American Journal of Hematology, 2020, 95, 672-690.	2.0	22
22	Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Annals of Hematology, 2020, 99, 1265-1271.	0.8	18
23	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	0.6	17
24	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2017, 58, 308-315.	0.6	16
25	A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties. Cancer, 2015, 121, 2303-2313.	2.0	15
26	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. Journal of Internal Medicine, 2017, 281, 611-619.	2.7	15
27	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	1.2	15
28	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	1.2	15
29	lbrutinib for the treatment of Waldenström macroglobulinemia. Expert Review of Hematology, 2015, 8, 569-579.	1.0	14
30	Newer Therapies for Amyloid Cardiomyopathy. Current Heart Failure Reports, 2016, 13, 237-246.	1.3	13
31	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. American Journal of Hematology, 2019, 94, 439-445.	2.0	12
32	Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood, 2022, 140, 2443-2450.	0.6	12
33	Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. British Journal of Haematology, 2020, 189, 1074-1082.	1.2	11
34	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	1.2	10
35	Will we be able to afford a cure in multiple myeloma?. Leukemia and Lymphoma, 2018, 59, 1-2.	0.6	10
36	Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies, 2019, 8, 34.	1.2	10

#	Article	IF	CITATIONS
37	Emerging drugs for the treatment of light chain amyloidosis. Expert Opinion on Emerging Drugs, 2020, 25, 299-317.	1.0	10
38	lmmunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	1.7	9
39	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	1.4	9
40	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	0.6	9
41	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	1.3	8
42	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 2020, 191, 442-452.	1.2	8
43	How do we manage t(11;14) plasma cell disorders with venetoclax?. British Journal of Haematology, 2022, 199, 31-39.	1.2	8
44	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 442-459.	0.2	7
45	Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?. Journal of Clinical Oncology, 2022, 40, 3099-3102.	0.8	7
46	The role of stem cell transplantation in Waldenstrom's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 229-240.	0.7	6
47	+1q: amplifying the bad genes in myeloma. Leukemia and Lymphoma, 2017, 58, 1771-1773.	0.6	6
48	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. Blood Cancer Journal, 2021, 11, 121.	2.8	6
49	Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 545-548.	0.2	6
50	Rethinking mechanisms of neurotoxicity with BCMA directed therapy. Critical Reviews in Oncology/Hematology, 2021, 166, 103453.	2.0	6
51	A case of Hodgkin's lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD. Journal of Blood Medicine, 2015, 6, 93.	0.7	5
52	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 1143-1156.	1.1	5
53	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. Journal of Hematology (Brossard, Quebec), 2019, 8, 1-10.	0.4	5
54	Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have highâ€risk cytogenetics: A metaâ€analysis of randomized controlled trials. Cancer, 2022, , .	2.0	5

#	Article	IF	CITATIONS
55	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	1.4	4
56	Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma. JAMA Oncology, 2019, 5, 1095.	3.4	4
57	Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population. Leukemia and Lymphoma, 2019, 60, 3544-3551.	0.6	4
58	Infection risk with carfilzomib in multiple myeloma: a systematic review and metaâ€analysis of randomised controlled trials. British Journal of Haematology, 2020, 190, e95-e97.	1.2	4
59	Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?. Cancer, 2021, 127, 31-34.	2.0	4
60	Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. Current Hematologic Malignancy Reports, 2021, 16, 148-161.	1.2	4
61	Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma. British Journal of Haematology, 2020, 189, e112-e113.	1.2	3
62	Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome. Korean Journal of Internal Medicine, 2014, 29, 827.	0.7	3
63	Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the <i>PRISM</i> score. Blood, 2020, 136, 29-30.	0.6	2
64	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	1.4	1
65	Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status. Blood, 2019, 134, 5248-5248.	0.6	1
66	A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2021, 138, 4763-4763.	0.6	1
67	Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis. American Journal of Hematology, 2022, 97, .	2.0	1
68	Anticancer Drug Approvals in the Past Decade—Quality vs Quantity. JAMA Network Open, 2021, 4, e2139178.	2.8	1
69	Phase II clinical trials for Waldenstrom's macroglobulinemia. Expert Opinion on Orphan Drugs, 2015, 3, 537-547.	0.5	Ο
70	Life beyond bortezomib: increasing treatment options in refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1251-1253.	0.6	0
71	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. , 2018, , 551-571.		0
72	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival Journal of Clinical Oncology, 2016, 34, 8016-8016.	0.8	0

#	Article	IF	CITATIONS
73	Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation Journal of Clinical Oncology, 2017, 35, 8020-8020.	0.8	Ο
74	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition Journal of Clinical Oncology, 2017, 35, e19532-e19532.	0.8	0
75	Impact of bilateral mastectomy with or without immediate reconstruction on time to subsequent therapy in breast cancer in a community oncology clinic Journal of Clinical Oncology, 2017, 35, e18154-e18154.	0.8	Ο
76	Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis. Blood, 2021, 138, 4726-4726.	0.6	0
77	Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans. Blood, 2021, 138, 431-431.	0.6	Ο
78	Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis. Leukemia and Lymphoma, 2022, , 1-5.	0.6	0